Splenic diffuse red-pulp small B-cell lymphoma associated with hepatitis B virus: a report of two cases

Kerbauy, Mariana Nassif; Fernandes, Carolina M.; Bezerra, Evandro D.; Lage, Luis Alberto de Padua Covas; Siqueira, Sheila Aparecida Coelho; Pereira, Juliana

doi:10.1590/1516-3180.2016.0035130416

Cited by 10 publications

(11 citation statements)

References 29 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, some studies have shown coexistence between chronic hepatitis B virus infection and splenic lymphomas, particularly SMZL, suggesting a new etiological association for this neoplasm. Similar to that observed in HCV positive cases, treatment for HBV with antiviral agents is capable of inducing neoplasm remission [23][24][25][26]. SMZL is usually an indolent and chronic disease, with a median overall survival exceeding 10 years [2,15,16,18].…”

Section: Discussionmentioning

confidence: 72%

Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Splenic marginal zone lymphoma (SMZL) is a rare lymphoid B-cell malignant neoplasm with primary involvement of the spleen. It is a chronic disease, of indolent behavior and prolonged survival. However, 25% of cases have higher biological aggressiveness, propensity for histological transformation to high grade B-cell non-Hodgkin lymphoma and shortened survival. Recognition of these cases of reserved outcome is important for selecting a risk-adapted therapeutic approach in a resource-poor settings. Methods We described clinical and epidemiological characteristics, survival analysis and prognostic factors in a retrospective cohort of 39 SMZL patients, treated in Latin America. Results We observed a predominance of female (71.8%), median age of 63 years and higher incidence of B symptoms (56.4%) and extra-splenic involvement (87.1%) than in European and North-American series. With a median follow-up of 8.7 years (0.6-20.2 years), estimated 5-year overall survival (OS) and progression-free survival (PFS) were 76.9% and 63.7%, respectively. Factors with adverse prognostic impact on OS and PFS were Hb < 100 g/L, platelet count < 100 x 10 9 /L, albumin < 3.5 g/dL, LDH > 480 U/L and high-risk Arcaini and SMZL/WG scores. Despite a relative low number of patients, no superiority was observed among the therapeutic regimens used including rituximab monotherapy, splenectomy and cytotoxic chemotherapy. Conclusion Therefore, in resource-poor settings, where access to immunotherapy is not universal for all SMZL patients, we suggest that first-line should consist on rituximab therapy for elderly patients or with high surgical risk or with at least 1 risk factor identified in our study. Remainders can be safely managed with splenectomy.

show abstract

Section: Discussionmentioning

confidence: 72%

Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Utilizando o mesmo bioestimulante dessa pesquisa, na cultura do girassol, Junqueira et al (2017) observaram relação direta entre o aumento da massa seca de plântulas e da dose do produto, semelhante ao resultado encontrado na temperatura de 20°C. O incremento de massa seca das raízes deve-se a presença de giberelinas que participam ativamente do crescimento das células radiculares (KERBAUY, 2004) e segundo McDonald & Khan (1983), estes hormônios influenciam o metabolismo proteico, aumentando a taxa de síntese de proteínas nas sementes.…”

Section: Resultsunclassified

Initial development of millet with use of biostimulant under different temperatures

Diesel¹,

Silva²

2020

Sci. Elec. Arch.

View full text Add to dashboard Cite

Millet is an important summer grass used as forage grass due to good bromatological characteristics and easy adaptation to Brazilian environmental conditions. However, when sowing the crop early in the southern region, situations may occur where low temperatures affect germination and seedling development. Thus, the present work had the objective of evaluating the germination and initial development of millet using Biozyme TF® biostimulant as a way to attenuate the effects of different temperatures. The experimental design was completely randomized, in a factorial scheme 3 x 5 (temperatures x doses) with four replicates each. The temperatures used were 15 °C, 20 °C and 25 °C and the doses used were: 0 (control); 0.25; 0.5; 0.75 and 1 ml kg-1. After the treatment, the seeds were evaluated by: germination test, germination speed index, shoot and root length and seedling dry mass. The data obtained were submitted to analysis of variance with Sisvar® software and, when found significant, the regression analysis was performed. The germination of millet seeds is favored, under low temperature stress conditions, with seed treatment at the dose of 0.50 ml kg-1 of biostimulant. The biostimulant does not influence millet germination speed index. Under low temperature thermal stress the biostimulant minimally increases the length and dry mass accumulation of millet seedlings and attenuates the negative effects on root growth. The accumulation of dry mass of the roots decreased with increasing dose of the biostimulant under thermal stress condition.

show abstract

“…In a retrospective study of 17 cases with SDRPL, liver involvement was reported in 18% of cases while erythematous and pruritic skin papules were seen in 10% of patients [7]. Concurrent chronic hepatitis B infection has also been described in two cases of SDRPL [8].…”

Section: Clinical Presentationmentioning

confidence: 99%

Splenic B-Cell Lymphoma/Leukemia, Unclassifiable

Tizro¹,

Abdulbaki²,

Aggarwal³

et al. 2022

Lymphoma

View full text Add to dashboard Cite

Splenic B-cell lymphoma/leukemia, which is unclassifiable, includes low-grade B-cell lymphoproliferative disorders that do not fit into any other splenic lymphoid neoplasm based on current WHO classification. Presently, two provisional entities, splenic diffuse red pulp small B-cell lymphoma (SDRPL) and hairy-cell leukemia variant (HCL-v), are the most recognizable members of this group. SDRPL is an uncommon malignancy representing less than 1% of all non-Hodgkin lymphomas. Frequent clinical manifestations include splenomegaly and lymphocytosis. SDRPL is currently considered a diagnosis of exclusion and requires clinical and paraclinical correlation, including blood smear, bone marrow and spleen morphology, and the correct immunophenotype (typically positive for CD20, DBA.44, and IgG; and negative for CD5, CD10, CD23, CD43, annexin A1, CD11c, CD25, CD103, and CD123), and cytogenetic findings. Cyclin D3 is expressed in the majority of SDRPL in contrast to other types of small B-cell lymphomas. HCL-v is a less common disease accounting for 0.4% of all chronic lymphoproliferative disorders. It resembles classical HCL and SDRPL by diffusely infiltrating the splenic red pulp but is considered biologically unrelated. Splenomegaly and atypical lymphocytosis without monocytopenia are common. Distinguishing features of HCL-v include morphology, immunophenotype (the absence of CD25, CD200, CD123, annexin A1, and TRAP), genotype (wild-type BRAF), and prognosis.

show abstract

Splenic diffuse red-pulp small B-cell lymphoma associated with hepatitis B virus: a report of two cases

Cited by 10 publications

References 29 publications

Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center

Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center

Initial development of millet with use of biostimulant under different temperatures

Splenic B-Cell Lymphoma/Leukemia, Unclassifiable

Contact Info

Product

Resources

About